A Randomized, Open-Label, Controlled, Phase III Trial Comparing guaranteed Mesenchymal Stem Cell 1 (gMSC1) versus Microfracture (MFx) in Patients with Symptomatic Articular Cartilage Defects or Osteochondritis Dissecans in the Knee
Phase of Trial: Phase III
Latest Information Update: 29 Nov 2017
At a glance
- Drugs GMSC1-TWO-CELLS (Primary)
- Indications Cartilage disorders
- Focus Registrational; Therapeutic Use
- Sponsors Two Cells
- 29 Nov 2017 According to a TWOCELLS media release, the first patient has been performed surgery in this trial.
- 07 Aug 2017 Status changed from not yet recruiting to recruiting.
- 01 Jun 2017 New trial record